Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandala, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus JM van den EertweghJean Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C. Lorigan, Robert Lupinacci, Clemens Krepler, Nageatte Ibrahim, Michal Kicinski, Sandrine Marreaud, Alexander C. van Akkooi, Stefan Suciu, Caroline Robert
Research output: Contribution to journal › Article › peer-review
66Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma'. Together they form a unique fingerprint.